Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand [PDF]
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -- Germany, the Netherlands, and New Zealand -- and examines their effects on the availability of new drugs, reimbursement levels, manufacturer ...
Jonathan D. Ketcham, Patricia M. Danzon
core
Advances in Biosimilars: A Systematic Review of Machine Learning Applications. [PDF]
Pharmaceuticals (Basel)Duarte V, Bas TG.
europepmc +1 more source
, 2017 Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Walsh T +8 more
core
Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study. [PDF]
Clin OphthalmolChakraborty D +7 more
europepmc +1 more source
Overcoming the Constraints of Biosimilar Legislation through Creating Transparency
, 2016 : Biosimilar pharmaceuticals are new lower-cost drugs awaiting large-scale approval within the United States (U.S). Biosimilar pharmaceuticals or simply biosimilars, are complex, large-molecule, and biologically-derived drugs that are deemed molecularly ...
core
Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis. [PDF]
Arch OsteoporosSiachalinga L +7 more
europepmc +1 more source
Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products
IOSR Journal of Pharmacy (IOSRPHR), 2014 openaire +1 more source
Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets [PDF]
This paper examines the role of regulation and competition in generic markets. Generics offer large potential savings to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic entry and uptake
Patricia M. Danzon, Michael F. Furukawa
core
Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]
Indian J OphthalmolChakraborty D, Sinha TK, Boral S, Das A.
europepmc +1 more source
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
, 2017 Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
Zabransky M +5 more
core